These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 33970588)

  • 41. Incorporating New Medications in Diabetes Care.
    Comi RJ
    Ann Intern Med; 2015 Nov; 163(9):719-20. PubMed ID: 26458033
    [No Abstract]   [Full Text] [Related]  

  • 42. Second line therapy: type 2 diabetic subjects failing on metformin GLP-1/DPP-IV inhibitors versus sulphonylurea/insulin: for GLP-1/DPP-IV inhibitors.
    Kumar A
    Diabetes Metab Res Rev; 2012 Dec; 28 Suppl 2():21-5. PubMed ID: 23280862
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cardiovascular disease and oral agent glucose-lowering therapies in the management of type 2 diabetes.
    Home P
    Diabetes Technol Ther; 2012 Jun; 14 Suppl 1():S33-42. PubMed ID: 22650223
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dipeptidyl peptidase-4 inhibitor compared with sulfonylurea in combination with metformin: cardiovascular and renal outcomes in a propensity-matched cohort study.
    Kim KJ; Choi J; Lee J; Bae JH; An JH; Kim HY; Yoo HJ; Seo JA; Kim NH; Choi KM; Baik SH; Kim SG; Kim NH
    Cardiovasc Diabetol; 2019 Mar; 18(1):28. PubMed ID: 30857540
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Saxagliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes.
    Lam S; Saad M
    Cardiol Rev; 2010; 18(4):213-7. PubMed ID: 20539105
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparative risk for cardiovascular diseases of dipeptidyl peptidase-4 inhibitors vs. sulfonylureas in combination with metformin: Results of a two-phase study.
    Enders D; Kollhorst B; Engel S; Linder R; Verheyen F; Pigeot I
    J Diabetes Complications; 2016; 30(7):1339-46. PubMed ID: 27245402
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Non-insulin pharmacological therapies for treating type 1 diabetes.
    Frandsen CS; Dejgaard TF; Madsbad S; Holst JJ
    Expert Opin Pharmacother; 2018 Jun; 19(9):947-960. PubMed ID: 29991320
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pharmacological management of type 2 diabetes mellitus: an update.
    El-Kaissi S; Sherbeeni S
    Curr Diabetes Rev; 2011 Nov; 7(6):392-405. PubMed ID: 21846326
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cardiovascular Protection in the Treatment of Type 2 Diabetes: A Review of Clinical Trial Results Across Drug Classes.
    Paneni F; Lüscher TF
    Am J Cardiol; 2017 Jul; 120(1S):S17-S27. PubMed ID: 28606340
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Management of hyperglycaemia with non-insulin drugs in adult patients with type 2 diabetes].
    Álvarez-Guisasola F; Orozco-Beltrán D; Cebrián-Cuenca AM; Ruiz Quintero MA; Angullo Martínez E; Ávila Lachica L; Ortega Millán C; Caride Miana E; Navarro-Pérez J; Sagredo Perez J; Barrot de la Puente J; Cos Claramunt FX
    Aten Primaria; 2019; 51(7):442-451. PubMed ID: 31320123
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differential cardiovascular outcomes after dipeptidyl peptidase-4 inhibitor, sulfonylurea, and pioglitazone therapy, all in combination with metformin, for type 2 diabetes: a population-based cohort study.
    Seong JM; Choi NK; Shin JY; Chang Y; Kim YJ; Lee J; Kim JY; Park BJ
    PLoS One; 2015; 10(5):e0124287. PubMed ID: 25992614
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Newer anti - diabetic therapies and chronic kidney disease].
    Di Lullo L; Ronco C; Barbera V; Cozzolino M; Santoboni F; Villani A; De Pascalis A; Bellasi A
    G Ital Nefrol; 2017; 34(1):. PubMed ID: 28177092
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effects of dipeptidyl peptidase-4 inhibitors on blood pressure in patients with type 2 diabetes: A systematic review and meta-analysis.
    Zhang X; Zhao Q
    J Hypertens; 2016 Feb; 34(2):167-75. PubMed ID: 26682782
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [New antidiabetic drugs: current status and future prospects - a review of the literature].
    Baranowska A; Stefanowicz-Rutkowska M; Matuszewski W; Bandurska-Stankiewicz E
    Wiad Lek; 2018; 71(8):1588-1598. PubMed ID: 30684345
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Drugs for type 2 diabetes.
    Med Lett Drugs Ther; 2019 Nov; 61(1584):169-178. PubMed ID: 31770362
    [No Abstract]   [Full Text] [Related]  

  • 56. The effect of a dual combination of noninsulin antidiabetic drugs on lipids: a systematic review and network meta-analysis.
    Dai X; Wang H; Jing Z; Fu P
    Curr Med Res Opin; 2014 Sep; 30(9):1777-86. PubMed ID: 24805140
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative Safety of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylureas and Other Glucose-lowering Therapies for Three Acute Outcomes.
    Gamble JM; Donnan JR; Chibrikov E; Twells LK; Midodzi WK; Majumdar SR
    Sci Rep; 2018 Oct; 8(1):15142. PubMed ID: 30310100
    [TBL] [Abstract][Full Text] [Related]  

  • 58. When metformin is not enough: Pros and cons of SGLT2 and DPP-4 inhibitors as a second line therapy.
    Avogaro A; Delgado E; Lingvay I
    Diabetes Metab Res Rev; 2018 May; 34(4):e2981. PubMed ID: 29320602
    [TBL] [Abstract][Full Text] [Related]  

  • 59. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Sulfonylureas or dipeptidyl peptidase (DPP-4) inhibitors in the management of type 2 diabetes: debate is not yet closed.
    Guillausseau PJ
    Curr Diab Rep; 2011 Dec; 11(6):461-2; author reply 463. PubMed ID: 21915770
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.